Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Here’s Why

Sysmex Corporation ADR (OTCMKTS:SSMXY) shares gapped down prior to trading on Wednesday . The stock had previously closed at $10.02, but opened at $9.45. Sysmex shares last traded at $9.43, with a volume of 1,633 shares traded.

Wall Street Analysts Forecast Growth

Separately, Zacks Research cut Sysmex from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Sysmex currently has an average rating of “Hold”.

Sysmex Price Performance

The company has a market capitalization of $5.96 billion, a P/E ratio of 24.93 and a beta of 1.07. The stock’s fifty day simple moving average is $9.03 and its 200-day simple moving average is $9.07. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 2.46.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings data on Thursday, May 14th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The business had revenue of $877.92 million during the quarter, compared to the consensus estimate of $862.45 million. Sysmex had a return on equity of 7.23% and a net margin of 7.13%.Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. On average, equities analysts forecast that Sysmex Corporation ADR will post 0.42 earnings per share for the current fiscal year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.